Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Phase 3

Terminated

• Conditions: Post-operative Pain
• Interventions: Drug: Buprenorphine Sublingual Spray; Drug: Placebo

• Registration Number: NCT02310581
• Lead Sponsor: INSYS Therapeutics Inc

Brief Summary

This is a phase 3, multicenter, randomized, double-blind, multiple-dose, parallel-group, placebo-controlled study to evaluate the safety and efficacy of up to 3 dosing regimens of Buprenorphine Sublingual (under the tongue) Spray and/or matching placebo in participants with moderate to severe postoperative pain after bunionectomy. The study will comprise 4 periods: the Screening Period, the Surgical Period, the Treatment Period, and the Follow-up Period.

Participants will be admitted to the study site on the morning of the scheduled surgery, will remain at the study site until postoperative Day 3 (a total of 3 nights at the study site), and will return for the Follow-up Visit 5 to 9 days after surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-12-01
• Study First Submitted QC: 2014-12-04
• Study First Posted: 2014-12-08
• Study Start: 2015-02-24
• Primary Completion: 2015-03-19
• Study Completion: 2015-03-19
• Disposition First Submitted: 2015-12-07
• Disposition First Submitted QC: 2016-01-04
• Disposition First Posted: 2016-02-03
• Status Verified: 2017-06
• Results First Submitted: 2017-06-01
• Results First Submitted QC: 2017-08-03
• Last Update Submitted: 2017-08-03
• Results First Posted: 2017-08-09
• Last Update Posted: 2017-08-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Meets protocol-specified criteria for qualification and contraception
• Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
• Is willing and able to comply with study requirements (including diet, alcohol, and smoking restrictions), complete the pain evaluations, remain at the study site for three days, and return for follow up between 7 and 9 days after surgery.

Read More

Exclusion Criteria

• History or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters

• Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

  1. the safety or well-being of the participant or study staff
  2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
  3. the analysis of results

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Buprenorphine 1.0 mg BID	Placebo	Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
Buprenorphine 0.5 mg TID	Placebo	Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
Buprenorphine 1.0 mg BID	Buprenorphine Sublingual Spray	Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
Buprenorphine 0.5 mg TID	Buprenorphine Sublingual Spray	Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
Placebo	Placebo	Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
Buprenorphine 1.0 mg TID	Buprenorphine Sublingual Spray	Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
Buprenorphine 1.0 mg TID	Placebo	Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.

Primary Outcome Measures

Name	Time	Method
Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48)	Baseline and 0 to 48 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain \[maximum (max)=10 at each time point\] and negative numbers indicate an increase in pain \[minimum (min)=-10 at each time point\]. The overall min and max are -10 and 10 times the number of hours specified; SPID-48 range is -480 to 480. The NRS SPID-48 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.

Secondary Outcome Measures

Name	Time	Method
NRS Mean Pain Intensity Difference (PID) at 4, 8, 24 and 48 Hours After Time 0	Baseline and 4, 8, 24 and 48 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). NRS PID is defined as the difference in pain at each scheduled timepoint relative to Baseline (PID=pain intensity at baseline - pain intensity at time point). A higher value of NRS PID score indicates a higher decrease in pain from Baseline.
NRS SPID Over 0 to 4 Hours After Time 0 (NRS SPID-4)	Baseline and 0 to 4 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 4 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain \[maximum (max)=10 at each time point\] and negative numbers indicate an increase in pain \[minimum (min)=-10 at each time point\]. The overall min and max are -10 and 10 times the number of hours specified; SPID-4 range is -40 to 40. The NRS SPID-4 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.
NRS SPID Over 0 to 8 Hours After Time 0 (NRS SPID-8)	Baseline and 0 to 8 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 8 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain \[maximum (max)=10 at each time point\] and negative numbers indicate an increase in pain \[minimum (min)=-10 at each time point\]. The overall min and max are -10 and 10 times the number of hours specified; SPID-8 range is -80 to 80. The NRS SPID-8 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.
NRS Mean Pain Intensity Score at 4, 8, 24 and 48 Hours After Time 0	4, 8, 24 and 48 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). A lower value indicates improvement in pain.
NRS SPID Over 0 to 24 Hours After Time 0 (NRS SPID-24)	Baseline and 0 to 24 hours after Time 0	Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 24 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain \[maximum (max)=10 at each time point\] and negative numbers indicate an increase in pain \[minimum (min)=-10 at each time point\]. The overall min and max are -10 and 10 times the number of hours specified; SPID-24 range is -240 to 240. The NRS SPID-24 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.
Percentage of Participants Who Used Rescue Medication for Pain	From Time 0 (first dose of study drug) up to Day 9	The percentage of participants who needed to take an alternate medication for pain relief during the study.